News

Sarepta Therapeutics: Rebuilding The Thesis After Hitting Rock Bottom
Despite setbacks, Sarepta’s gene therapy pipeline and market leadership in DMD present a high-risk, high-reward setup. Read ...
Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures
The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.
Stocktwits on MSN6h
Sarepta Pauses DMD Gene Therapy Trial After Second Death; Retail Traders Brush Off Risk
Retail investor chatter around Sarepta Therapeutics surged on Sunday after the company announced it had suspended shipments ...
GEN - Genetic Engineering and Biotechnology News9h
Second DMD Patient Dies After Treatment with Sarepta Gene Therapy
Sarepta Therapeutics said it has temporarily suspended shipments of Elevidys® (delandistrogene moxeparvovec-rokl) for ...
2nd death reported in Sarepta gene therapy trial for Duchenne muscular dystrophy
Sarepta Therapeutics ( NASDAQ: SRPT) reported a second fatality from acute liver failure in a patient treated with its gene ...
Sarepta reports second case of liver failure death after its gene therapy treatment
Sarepta Therapeutics on Sunday said there had been a second reported case of acute liver failure resulting in death after a patient received the company's gene therapy ...
Belfast Live18h
Charity backs brave NI boy's campaign to "end cruel postcode lottery" for drug
The estimated cost that Belfast Trust has produced seems high and does not align with any other figures we have seen from ...
Sarepta Reports Second Death of Patient Using Its Gene Therapy
Sarepta Therapeutics Inc. said a second patient has died of acute liver failure after being treated with its gene therapy for ...